A Phase 4 interventional study of Rosuvastatin and HMG CoA inhibitor in Hypercholesteremia, sponsored by AstraZeneca. Completed at 27 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-08-31.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.
Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 28th largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2005, is one of 15 in phase 4, and was the 8th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 214 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 203 across the 57 interventional studies. Of the 53 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 59 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
60 studies in Hypercholesterolemia by AstraZeneca: 3 open now, 3 under way, 3 of them phase 3. Of 55 finished, 7 (13%) have results posted.
Among the 60 studies in Hypercholesterolemia by AstraZeneca, this one is the 23rd largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2005, is one of 5 in phase 4, and was the 7th registered.
AstraZeneca’s Hypercholesterolemia studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 59 studies testing rosuvastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 60 in Hypercholesterolemia:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate that 76 weeks of treatment with rosuvastatin calcium 2.5-20 mg results in no progression of coronary artery atherosclerotic volume as measured by intravascular ultrasonography (IVUS) imaging in hypercholesterolaemic subjects with coronary heart disease (CHD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.5-20 mg
3-hydroxy-3-methylglutaryl-coenzyme A
Percent Change From Baseline (Before the Start of Rosuvastatin Treatment) to Week 76 in the Plaque Volume (PV)
Plaque volume will be assessed by volumetric analysis with the echoPlaque2 system (Indec Systems Inc). Baseline and follow-up IVUS images will be reviewed side-by-side on a display, and the target segment selected. The target segment to be monitored will be determined in a non-PCI site (\>5 mm proximal or distal to the PCI site) with a reproducible index such as side branches, calcifications, or stent edges.
Time frame: Baseline and 76 weeks
Change From Baseline to Week 76 in Plaque Volume (PV) in the Target Lesion
Target Lesion indicates Coronary plaque composition of culprit lesions.
Time frame: Baseline - 76Weeks
Percent Change From Baseline to Specified Measurement Time Points in Low-density Lipoprotein (LDL-C)
Time frame: Baseline - 76Weeks
Percent Change in High-sensitivity C-reactive Protein (HS-CRP) From Baseline to Specified Measurement Time Points
Time frame: Baseline - 76Weeks
| Milestone | Rosuvastatin |
|---|---|
| Started | 214 |
| Observation period | 214 |
| Treatment period | 214 |
| Completed | 126 |
| Not completed | 88 |
| Withdrew: Adverse event | 27 |
| Withdrew: Withdrawal by subject | 13 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Did not receive study drug | 1 |
| Withdrew: Incomplete ivus | 45 |
Plaque volume will be assessed by volumetric analysis with the echoPlaque2 system (Indec Systems Inc). Baseline and follow-up IVUS images will be reviewed side-by-side on a display, and the target segment selected. The target segment to be monitored will be determined in a non-PCI site (\>5 mm proximal or distal to the PCI site) with a reproducible index such as side branches, calcifications, or stent edges.
| Percent Change | Rosuvastatin |
|---|---|
| Percent Change From Baseline (Before the Start of Rosuvastatin Treatment) to Week 76 in the Plaque Volume (PV) | 14.1 ± -5.066 |
Target Lesion indicates Coronary plaque composition of culprit lesions.
| mg/dL | Rosuvastatin |
|---|---|
| Change From Baseline to Week 76 in Plaque Volume (PV) in the Target Lesion | 12.074 ± -5.259 |
| Percent change | Rosuvastatin |
|---|---|
| Percent Change From Baseline to Specified Measurement Time Points in Low-density Lipoprotein (LDL-C) | 16.9 ± -38.6 |
| Percent change | Rosuvastatin |
|---|---|
| Percent Change in High-sensitivity C-reactive Protein (HS-CRP) From Baseline to Specified Measurement Time Points | 18.1 ± 291.3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin | — | 98/213 (46%) | 588/214 (274.8%) |
| Event | Rosuvastatin |
|---|---|
| Coronary Artery StenosisCardiac disorders | 21/213 |
| Angina PectorisCardiac disorders | 7/213 |
| Cardiac Failure CongestiveCardiac disorders | 2/213 |
| Prinzmetal AnginaCardiac disorders | 2/213 |
| PyrexiaGeneral disorders | 2/213 |
| Hepatic Function AbnormalHepatobiliary disorders | 2/213 |
| Coronary Artery RestenosisInjury, poisoning and procedural complications | 2/213 |
| In-Stent Coronary Artery RestenosisInjury, poisoning and procedural complications | 2/213 |
| Subdural HaematomaInjury, poisoning and procedural complications | 2/213 |
| C-Reactive Protein IncreasedInjury, poisoning and procedural complications | 2/213 |
| Event | Rosuvastatin |
|---|---|
| NasopharyngitisInfections and infestations | 69/214 |
| Gamma-Glutamyltransferase IncreasedInfections and infestations | 48/214 |
| Blood Creatine Phosphokinase IncreasedInfections and infestations | 43/214 |
| Alanine Aminotransferase IncreasedInfections and infestations | 38/214 |
| Blood Urine PresentInfections and infestations | 33/214 |
| Protein Urine PresentInfections and infestations | 31/214 |
| Aspartate Aminotransferase IncreasedInfections and infestations | 28/214 |
| Glucose Urine PresentInfections and infestations | 28/214 |
| Blood Pressure IncreasedInfections and infestations | 22/214 |
| Blood Alkaline Phosphatase IncreasedInfections and infestations | 20/214 |
| Age Continuous(years) | Rosuvastatin |
|---|---|
| Years | 62.6 ± 7.7 |
| Sex: Female, Male(Participants) | Rosuvastatin |
|---|---|
| Female | 30 |
| Male | 96 |
The record gives a start of Oct 2005, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin